Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MYGN 
Myriad Genetics Inc (MYGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: MYGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.95
1 Year Target Price $7.95
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 2 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.64% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 748.08M USD | Price to earnings Ratio - | 1Y Target Price 7.95 |
Price to earnings Ratio - | 1Y Target Price 7.95 | ||
Volume (30-day avg) 15 | Beta 1.98 | 52 Weeks Range 3.76 - 19.60 | Updated Date 11/1/2025 |
52 Weeks Range 3.76 - 19.60 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.0132 | Actual - |
Profitability
Profit Margin -47.45% | Operating Margin (TTM) -5.87% |
Management Effectiveness
Return on Assets (TTM) -5.44% | Return on Equity (TTM) -70.03% |
Valuation
Trailing PE - | Forward PE 54.05 | Enterprise Value 783617380 | Price to Sales(TTM) 0.9 |
Enterprise Value 783617380 | Price to Sales(TTM) 0.9 | ||
Enterprise Value to Revenue 0.94 | Enterprise Value to EBITDA -23.47 | Shares Outstanding 93044627 | Shares Floating 85619666 |
Shares Outstanding 93044627 | Shares Floating 85619666 | ||
Percent Insiders 2.9 | Percent Institutions 100.09 |
Upturn AI SWOT
Myriad Genetics Inc
Company Overview
History and Background
Myriad Genetics Inc. was founded in 1991. It initially focused on developing genetic tests for cancer risk assessment. Over time, it expanded its portfolio to include diagnostic, companion diagnostic, and pharmacogenomic tests across various medical specialties.
Core Business Areas
- Oncology: Provides testing to assess an individual's risk for hereditary cancers, including breast, ovarian, colon, prostate, and melanoma.
- Women's Health: Offers prenatal screening and reproductive health tests to assess risk for chromosomal abnormalities and other genetic conditions.
- Pharmacogenomics: Delivers testing that determines how a patient may respond to certain medications, enabling personalized treatment decisions.
Leadership and Structure
Paul J. Diaz is the President and CEO. The company has a typical corporate structure with departments such as Research & Development, Sales & Marketing, Finance, and Operations.
Top Products and Market Share
Key Offerings
- BRACAnalysis CDx: A genetic test for BRCA1 and BRCA2 genes to identify patients with ovarian cancer who are eligible for certain therapies. Competitors include Invitae (NVTA) and NeoGenomics (NEO). Market share is significant in the companion diagnostics for PARP inhibitors.
- Myriad Precise Oncology Solutions: Assesses tumor mutational burden (TMB), microsatellite instability (MSI) status, and other biomarkers to guide treatment decisions in cancer patients. Competitors include Foundation Medicine (owned by Roche) and Guardant Health (GH).
- Prolaris: A prostate cancer prognostic test that predicts disease aggressiveness. Competitors include Genomic Health's Oncotype DX Prostate and Decipher Biosciences. Market share is moderate and growing. Revenue data is not disaggregated by product.
- Vectra DA: A blood test for rheumatoid arthritis (RA) to help guide treatment decisions by quantifying RA disease activity. Competitors include Crescendo Bioscience (owned by Myriad Genetics) and others. Not broken down to a specific revenue number.
Market Dynamics
Industry Overview
The genetic testing market is experiencing rapid growth driven by advancements in technology, increasing awareness of personalized medicine, and the growing prevalence of genetic disorders and cancer. It is also influenced by regulatory policies and reimbursement landscapes.
Positioning
Myriad Genetics is a key player in the personalized medicine market, focusing on genetic testing for cancer risk assessment, diagnosis, and treatment guidance. Its competitive advantages include its established brand, proprietary technologies, and extensive database of genetic information.
Total Addressable Market (TAM)
The TAM for genetic testing is estimated to be in the billions of dollars annually. Myriad is positioned to capture a significant portion of this TAM through its diverse portfolio of tests and its focus on personalized medicine. The TAM can be found in various research reports and analyst estimates for the genetic testing industry, such as those from Grand View Research.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Extensive proprietary database of genetic information
- Diverse portfolio of diagnostic and companion diagnostic tests
- Strong relationships with healthcare providers
Weaknesses
- Reliance on patents for some tests
- Exposure to reimbursement pressures
- Competition from other genetic testing companies
- Past controversies regarding pricing practices
Opportunities
- Expanding into new therapeutic areas
- Developing new companion diagnostic tests
- Increasing adoption of personalized medicine
- Partnerships with pharmaceutical companies
Threats
- Changes in reimbursement policies
- Increased competition from new entrants
- Patent expirations
- Ethical and regulatory concerns about genetic testing
Competitors and Market Share
Key Competitors
- NVTA
- NEO
- GH
Competitive Landscape
Myriad Genetics faces intense competition in the genetic testing market. It differentiates itself through its established brand, proprietary technologies, and comprehensive test menu. However, it must continue to innovate and adapt to changing market dynamics to maintain its competitive position.
Major Acquisitions
Crescendo Bioscience
- Year: 2014
- Acquisition Price (USD millions): 270
- Strategic Rationale: Acquisition of Crescendo Bioscience increased market share in Rheumatoid Arthritis by acquiring the test Vestra DA.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been mixed, with periods of strong growth followed by periods of decline.
Future Projections: Analyst estimates project modest revenue growth in the coming years, driven by new product launches and increasing adoption of genetic testing. However, it depends on market expansion, reimbursement rates, and competition.
Recent Initiatives: Focus on precision medicine solutions, expanding test menu, and cost-cutting initiatives. They are focused on increasing the margins by reducing costs.
Summary
Myriad Genetics holds a strong position in the genetic testing market due to its established brand and diverse test portfolio. However, profitability remains a challenge, and they should continue to innovate to combat the competition. Regulatory and reimbursement risks also require careful management, however they are poised for modest growth in the long run.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and may be subject to change. Market share data is estimated and may not be precise. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myriad Genetics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 1995-10-05 | President, CEO & Director Mr. Samraat S. Raha | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2700 | Website https://www.myriad.com |
Full time employees 2700 | Website https://www.myriad.com | ||
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.